Calculus invests £2m in Oxford BioTherapeutics

London, 3 August 2018: Calculus Capital has invested £2m in Oxford BioTherapeutics (OBT), a clinical-stage oncology company that is developing next-generation cancer treatments. OBT has a strong pipeline of ‘immune-oncology’ (IO) therapies that are intended to provide more targeted, specialised … Continued

Calculus invests £2m in CloudTrade

CloudTrade’s technology – which has been patented in Europe, the US and Australia – enables companies to automatically process electronic documents such as invoices and sales orders received by email. The software extracts information from a human-readable, machine-generated document, such … Continued

Calculus View on UK Industrial Strategy

The Prime Minister delivered a speech this week outlining the Government’s Industrial Strategy which aims to tackle the ‘Four Grand Challenges’ facing the world today, along with a target that UK R&D spend reaches 2.4% of GDP by 2027. The … Continued

Calculus completes a further investment in Mologic

Calculus Capital has completed a further investment into a growth capital investment round for Mologic alongside Foresight Group, who led the round. Mologic is a Point of Care (POC) diagnostics company that provides Contract Research (CRO) and manufacturing (CMO) services. … Continued

Calculus completes two further investments

On 29 March, Calculus completed two follow-on investments into portfolio companies Weedingtech and Quai. These investments represent further funding and support for businesses we have previously backed as they continue to grow. Weedingtech is a multi-award winning cleantech company and … Continued

Calculus view on ‘significant’ VCT rule changes

Much attention has been paid to the changes made to EIS investing and understandably so – they represent a step change for the industry.  Less attention, however, has been paid to the changes made to VCT rules, which are far … Continued